| A Study to Evaluate the Use of Stavudine (d4T) to Treat AIDS Dementia Complex (NCT00002246) | Bristol-Myers Squibb | 1997-10-01 |
| A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection (NCT00002176) | Bristol-Myers Squibb | 1997-05-01 |
| A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection (NCT00002177) | Bristol-Myers Squibb | 1997-05-01 |
| Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris (NCT00287547) | Bristol-Myers Squibb | 1997-03-01 |
| The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine (NCT00002371) | Bristol-Myers Squibb | 1996-06-01 |
| A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris (NCT00277225) | Bristol-Myers Squibb | 1995-11-01 |
| Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris (NCT00306878) | Bristol-Myers Squibb | 1995-08-01 |
| A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection. (NCT00002349) | Bristol-Myers Squibb | 1995-01-01 |
| Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC (NCT00002057) | Bristol-Myers Squibb | |
| A Comparison of Zidovudine (AZT) and Stavudine in HIV-Infected Patients (NCT00002307) | Bristol-Myers Squibb | |
| Expanded Access for Dasatinib (NCT00454753) | Bristol-Myers Squibb | |
| Expanded Access for Iberdomide (NCT07434960) | Bristol-Myers Squibb | |
| The Safety and Effectiveness of Megace in HIV-Infected Women (NCT00002345) | Bristol-Myers Squibb | |
| Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (NCT02475382) | Bristol-Myers Squibb | |
| A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine (NCT00002280) | Bristol-Myers Squibb | |
| A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers (NCT00002261) | Bristol-Myers Squibb | |
| The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors (NCT00002420) | Bristol-Myers Squibb | |
| Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine (NCT00002035) | Bristol-Myers Squibb | |
| Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma (NCT02186249) | Bristol-Myers Squibb | |
| A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia (NCT00002067) | Bristol-Myers Squibb | |
| EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C (NCT02097966) | Bristol-Myers Squibb | |
| Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients (NCT00002041) | Bristol-Myers Squibb | |
| A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV (NCT00002358) | Bristol-Myers Squibb | |
| Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma (NCT03126617) | Bristol-Myers Squibb | |
| A Study of Stavudine in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drugs (NCT00002308) | Bristol-Myers Squibb | |
| Expanded Access for Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy (NCT00677313) | Bristol-Myers Squibb | |
| Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis (NCT00279760) | Bristol-Myers Squibb | |
| Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor (NCT05301972) | Bristol-Myers Squibb | |
| Clinical Trial Comparing Safety and Pharmacokinetics of Standard Antibiotic Therapy, Plus Aurexis® or Placebo, for Treatment of Staphylococcus Aureus Bacteremia (SAB) (NCT00198302) | Bristol-Myers Squibb | |
| Expanded Access for Mezigdomide (NCT06994117) | Bristol-Myers Squibb | |
| Expanded Access for Abatacept (NCT05170672) | Bristol-Myers Squibb | |
| A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir) (NCT00002028) | Bristol-Myers Squibb | |
| Expanded Access for Apixaban (NCT05187286) | Bristol-Myers Squibb | |
| A Belatacept Compassionate Use Study for Patients With a Kidney Transplant (NCT00719225) | Bristol-Myers Squibb | |
| A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes (NCT00002293) | Bristol-Myers Squibb | |
| Expanded Access for Repotrectinib (NCT05926232) | Bristol-Myers Squibb | |
| A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy (NCT00036621) | Bristol-Myers Squibb | |
| A Study of Different Doses of Megestrol Acetate in Patients With AIDS Who Have Anorexia and Malnutrition (NCT00002300) | Bristol-Myers Squibb | |
| Expanded Access to Nivolumab (Opdivo) (NCT03126643) | Bristol-Myers Squibb | |
| A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients (NCT00002168) | Bristol-Myers Squibb | |
| Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab (NCT05170685) | Bristol-Myers Squibb | |
| The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors (NCT00002418) | Bristol-Myers Squibb | |
| Expanded Access Treatment Protocol CA204-143 (NCT02368301) | Bristol-Myers Squibb | |
| Early Patient Access Treatment Use Protocol CA204-220 (NCT02856438) | Bristol-Myers Squibb | |
| A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C (NCT02161939) | Bristol-Myers Squibb | |
| A Study of Lobucavir in Patients With AIDS (NCT00002352) | Bristol-Myers Squibb | |
| Expanded Access for Relatlimab (NCT05170659) | Bristol-Myers Squibb | |
| A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs (NCT00002369) | Bristol-Myers Squibb | |
| Expanded Access for Anti-IL8 (NCT05210894) | Bristol-Myers Squibb | |
| Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer (NCT00099879) | Bristol-Myers Squibb | |
| Compassionate Use Trial for Unresectable Melanoma With Ipilimumab (NCT00495066) | Bristol-Myers Squibb | |
| A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine (NCT00002274) | Bristol-Myers Squibb | |
| Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer (NCT00103831) | Bristol-Myers Squibb | |
| Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation (NCT05162443) | Bristol-Myers Squibb | |